Placebo in the Investigation of Psychotropic Drugs, Especially Antidepressants

Science and Engineering Ethics

Volumn 10, Issue 1, 2004, Pages 135-142

  Pużyński, Stanisław ^a  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Antidepressants; Clinical investigation; Ethical; Legal; Methodological problems; Placebo; Psychotropic drugs

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; IMIPRAMINE; PLACEBO; PSYCHOTROPIC AGENT;

ANXIETY DISORDER; APPETITE DISORDER; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; HEALTH INSURANCE; HUMAN; LEGAL ASPECT; MEDICAL ETHICS; MENTAL DISEASE; MENTAL HEALTH CARE; METHODOLOGY; NAUSEA; PSYCHOPHARMACOLOGY; RELIABILITY; SEDATION; SIDE EFFECT;

EID: 1242321234     PISSN: 13533452     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11948-004-0070-0     Document Type: Conference Paper

References (35)

1. Benkert O., Maier W. (1990) The necessity of placebo application in psychotropic drug trials, Pharmacopsychiat 23: 203-205.
2. Carpenter W.T. and Conley R.R. (1999) Sense and nonsense: an essay on schizophrenia research ethics, Schizophrenia Res. 35: 219-225.
3. Gallant D.M. and Eichelman B. (1987) Ethical Dilemmas in Neuropsychopharmacologic Research in: Meltzer H.Y. (ed.): Psychopharmacology: The Third Generation of Progress, Raven Press, New York, pp. 1-15.
4. Klerman G.L. and Izen J.E. (1987) Psychopharmacology, in: Reich W.T. (ed.): Encyclopedia of Bioethics, vol. 1-4, Free Press, New York, and Collier McMillan Publ., London, pp. 1378-1386.
5. Klerman G.L. (1986) Scientific and ethical considerations in the use of placebo controls in clinical trials in psychopharmacology, Psychopharmacol. Bull 22: 25-32.
6. Levine R.J. (2002) Placebo controls in clinical trials of new therapies for which there are known effective treatments, in: Guess H.A., Kleinman A., Kusek J.W. and Engel L.W. (eds): The Science of the Placebo: Toward an Interdisciplinary Research Agenda, British Medical Journal Books, London, pp. 264-280.
7. Lieberman J.A. (1996) Ethical dilemmas in clinical research with human subjects: an investigator's perspective, Psychopharmacol. Bull. 32: 19-25.
8. Lieberman J.A., Troup S., Laska E., Volavka J., Gelenber A., Rush A.J. et al. (1999) Issues in clinical research design: Principles, practices and controversies, in: Pincus H.A., Lieberman J.A. and Ferris S. (eds): Ethics in Psychiatric Research: A Resource Manual for Human Subjects Protection. American Psychiatric Association, Washington, DC, pp. 23-60.
9. Pużyński S. (1995) Problemy etyczne i prawne stosowania leków psychotropowych w świetle postanowień miȩdzynarodowych (Ethical and legal problems of psychotropic drug use in the light of international conventions) in: Siwiak-Kobayashi M. and Leder S. (eds), Psychiatria i Etyka (Psychiatry a. Ethics), Biblioteka Psychiatrii Polskiej, Kraków, pp. 67-76.
10. Rickels K. (1986) Use of placebo in clinical trials, Psychopharmacol Bull. 22: 19-24.
11. Woggon B. (1992) Methodology of measuring the efficacy of antidepressants - European viewpoint, Psychopharmacology 106: S90-S92.
12. Freedman B. (1990) Placebo-controlled trials and the logic of clinical purpose, IRB, Res. Human Subj. Res. 12: 1-6.
13. Freedman B., Weijer C. and Glass R.C. (1996) Placebo orthodoxy in clinical research. I. empirical and methodological myths, J. Law Med. Ethics 24: 243-251.
14. Miller F.G. (2000) Placebo-controlled trials in psychiatric research: an ethical perspective, Biol. Psychiatry 47: 707-717.
15. Steiner D.L. (1999) Placebo-controlled trials: when are they needed? Schizophrenia Res. 35: 201-210.
16. Weijer Ch. (1999) Placebo-controlled trials in schizophrenia, Schizophrenia Res. 35: 211-218.
17. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects: Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 29th WMA General Assembly, Tokyo, Japan, October 1975; the 35th WMA General Assembly, Venice, Italy, October 1983; the 41st WMA General Assembly, Hong Kong, September 1989; the 48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996; and the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000, Ferney-Voltaire, France, WMA, http://www.wma.net/e/policy/17c.pdf
18. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects: Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 29th WMA General Assembly, Tokyo, Japan, October 1975; the 35th WMA General Assembly, Venice, Italy, October 1983; the 41st WMA General Assembly, Hong Kong, September 1989; the 48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996; and the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000, Ferney-Voltaire, France, WMA, http://www.wma.net/e/policy/17c.pdf
19. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects: Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 29th WMA General Assembly, Tokyo, Japan, October 1975; the 35th WMA General Assembly, Venice, Italy, October 1983; the 41st WMA General Assembly, Hong Kong, September 1989; the 48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996; and the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000, Ferney-Voltaire, France, WMA, http://www.wma.net/e/policy/17c.pdf
20. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects: Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 29th WMA General Assembly, Tokyo, Japan, October 1975; the 35th WMA General Assembly, Venice, Italy, October 1983; the 41st WMA General Assembly, Hong Kong, September 1989; the 48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996; and the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000, Ferney-Voltaire, France, WMA, http://www.wma.net/e/policy/17c.pdf
21. Panel Discussion Placebo-controlled studies in schizophrenia; ethical and scientific perspectives, (1999) Schizophrenia Res. 35: 227-236.
22. Zipursky R.B. and Darby P. (1999) Placebo-controlled studies in schizophrenia - ethical and scientific perspectives: an overview of conference proceedings, Schizophrenia Res. 35: 189-200.
23. Fleischacker W.W. and Burns T. (2002) Feasibility of placebo-controlled trials of antipsychotic compound in Europe, Psychopharmacology 162: 82-89.
24. Khan A. and Khan S. (2003) Placebo in mood disorders: the tail that wags the dog, Current Opin. Psychiatr. 16: 35-39.
25. Leuchter A., Cook J.A., Witte E.A., Morgan M. and Abrams M. (2002) Changes in brain function of depressed subjects during treatment with placebo, Am. J. Psychiatry. 159: 122-129.
26. Ross D.C., Quitkin F.M. and Klein D.F. (2002) A typological model for estimation of drug and placebo effect in depression, J. Clin. Psychopharmacology 22: 414-418.
27. Stassen H.H., Angst J. and Delini-Stula A. (1997) Delayed onset of action of antidepressant drugs? Survey of recent results, Eur. Psychiatry 12: 166-176.
28. Quitkin F.M. and Klein D.F. (2000) What conditions are necessary to assess antidepressant efficacy? Arch. Gen. Psychiatry 57: 323-324.
29. Quitkin F.M., Rabkin J.G., Gerald J., Davis J.M. and Klein D.F. (2000) Validity of clinical trials of antidepressants, Am. J. Psychiatry 157: 327-337.
30. Quitkin F.M. (1999) Placebo, drug effects, and study design: a clinician's guide, Am. J. Psychiatry 156: 829-836.
31. Principles for the Protection of Persons with Mental Illness and for the Improvement of Mental Health Care, United Nations General Assembly, Resolution 119, 46th Session, December 17, 1991, In: Law and Psychiatry (1993) 16: 291-300.
32. Safjan M. (1998) Prawo I Medycyna (Law and Medicine), Oficyna Naukowa, Warszawa.
33. Emilien G. and Hackett D. (2000) Limitation of placebo-controlled trials in the assessment of the efficacy of antidepressants, Internat. J. Methods in Psychiatric Research 9, suppl.: S3-S10.
34. Barbui C., Violante A. and Garattini S. (2000) Does placebo help establish equivalence in trials of new antidepressants, Eur. Psychiatry 15: 268-273.
35. Carpenter W.T., Appelbaum P.S. and Levine R.J. (2003) The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia, Am. J. Psychiatry 160: 356-362.